The 10-second takeaway
For the quarter ended March 31 (Q1), Vascular Solutions met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share grew. GAAP earnings per share grew.
Gross margins dropped, operating margins contracted, net margins expanded.
Vascular Solutions booked revenue of $26.1 million. The six analysts polled by S&P Capital IQ expected a top line of $26.4 million on the same basis. GAAP reported sales were 9.5% higher than the prior-year quarter's $23.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.16. The six earnings estimates compiled by S&P Capital IQ predicted $0.15 per share. Non-GAAP EPS of $0.16 for Q1 were 14% higher than the prior-year quarter's $0.14 per share. GAAP EPS of $0.13 for Q1 were 8.3% higher than the prior-year quarter's $0.12 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 65.4%, 170 basis points worse than the prior-year quarter. Operating margin was 11.1%, 200 basis points worse than the prior-year quarter. Net margin was 8.2%, 20 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $27.4 million. On the bottom line, the average EPS estimate is $0.17.
Next year's average estimate for revenue is $108.8 million. The average EPS estimate is $0.67.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 97 members out of 108 rating the stock outperform, and 11 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 22 give Vascular Solutions a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is outperform, with an average price target of $18.21.
Looking for alternatives to Vascular Solutions? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Vascular Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Vascular Solutions Is Poised to Outperform
Market-trouncing returns could be written in this 5-star stock.
This Metric Suggests You're Right to Own Vascular Solutions.
Don't just ask, "How much inventory?" Ask, "What kind?"
Will Vascular Solutions Beat These Analyst Estimates?